Erik Bloomquist

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review”.

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2600

N/A

0DataRank · unranked

72 citations

Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell, Jennifer Gao +17 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2599

N/A

0DataRank · unranked

23 citations

Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L. Suzman, Suparna Wedam +18 more

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1054

N/A

0DataRank · unranked

175 citations

Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman +17 more

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1133

N/A

0DataRank · unranked

9 citations

Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang +8 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more